Приказ основних података о документу
The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART
dc.creator | Jevtović, Đorđe | |
dc.creator | Ranin, Jovan | |
dc.creator | Salemović, Dubravka | |
dc.creator | Pešić, I. | |
dc.creator | Dragović, G. | |
dc.creator | Zerjav, S. | |
dc.creator | Đurković-Đaković, Olgica | |
dc.date.accessioned | 2021-04-20T12:15:09Z | |
dc.date.available | 2021-04-20T12:15:09Z | |
dc.date.issued | 2008 | |
dc.identifier.issn | 0753-3322 | |
dc.identifier.uri | http://rimi.imi.bg.ac.rs/handle/123456789/205 | |
dc.description.abstract | Despite substantial benefits of HAART treatment of HIV-infected patients, cumulative long-term toxicity, including drug-induced hepatotoxicity, has emerged as an important complication. Thus, to examine the prevalence and risk of developing severe hepatic injury during HAART, we conducted a retrospective study in a cohort of 364 HIV-infected patients treated with HAART between January 1998 and May 2006, for whom data on alanine aminotransferase activity were available both before and during HAART. HCV co-infection was recorded in 35.4% of the series, but was found not to influence either the efficacy of HAART or survival. (P gt 0.05). Severe hepatotoxicity occurred in a total of 24 patients' (6.6%). Multivariate logistic regression defined HCV co-infection (OR 16.6, 95% CI 3.8-46.0, P lt 0.0001), and the use of SQV/RTV and d4T (OR 3.1, 95% CI 1.2-8.16, P = 0.02, and OR 7.1, 95% CI 1.0-54.5, P = 0.05, respectively) as independent risk factors for,aggravation-of hepatitis. In addition, there was a significant increase,in the probability of developing liver damage over years of treatment (Log rank, P lt 0.01). Conversely, the probability of developing hepatotoxicity was not associated with an increase, in the CD4 cell count to values,greater than 350/mu L (Log rank, P = 0.59). In conclusion, in the setting of chronic viral hepatitis, hepatotoxicity during HAART may be attributed to the cumulative toxicity of drugs that induce mitochondrial toxicity, along with particular PIs and/or NNRTIs. Furthermore, our data suggest prudent use of D-drugs, still common in resource-limited countries, in HCV co-infected patients.(c) 2006 Elsevier Masson SAS. All rights reserved. | en |
dc.publisher | Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux | |
dc.relation | info:eu-repo/grantAgreement/MESTD/MPN2006-2010/145002/RS// | |
dc.rights | restrictedAccess | |
dc.source | Biomedicine & Pharmacotherapy | |
dc.subject | HIV | en |
dc.subject | HAART | en |
dc.subject | hepatitis C | en |
dc.subject | drug hepatotoxicity | en |
dc.title | The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART | en |
dc.type | article | |
dc.rights.license | ARR | |
dc.citation.epage | 25 | |
dc.citation.issue | 1 | |
dc.citation.other | 62(1): 21-25 | |
dc.citation.rank | M22 | |
dc.citation.spage | 21 | |
dc.citation.volume | 62 | |
dc.identifier.doi | 10.1016/j.biopha.2006.12.005 | |
dc.identifier.pmid | 17223307 | |
dc.identifier.scopus | 2-s2.0-38149057512 | |
dc.identifier.wos | 000253247700005 | |
dc.type.version | publishedVersion |